D-0403-2022 Class II Terminated
FDA drug recall D-0403-2022 was initiated by Edge Pharma, LLC on Dec 6, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 7, 2023). Affected quantity: 627 syringes.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 2, 2022
- Initiation Date
- Dec 6, 2021
- Termination Date
- Jun 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 627 syringes
Product description
Gemcitabine, Sterile Intravesical Solution, Preservative Free, 1g/50mL (20 mg/mL), 50 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1566-50
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
nationwide
Code information
08-2021-18@1 12/14/2021, 08-2021-27@1 12/09/2021, 09-2021-01@4 12/14/2021, 09-2021-08@2 12/21/2021, 09-2021-14@6 01/05/2021, 09-2021-16@4 12/29/2021, 09-2021-17@4 12/30/2021, 09-2021-22@3 01/04/2022 & 10-2021-27@3 02/08/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0403-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026